A web‐based survey on the occurrence of emotional blunting in patients with major depressive disorder in Japan: Patient perceptions and attitudes DOI Creative Commons
Toshiaki Kikuchi, Jun‐ichi Iga, Masato Oosawa

et al.

Neuropsychopharmacology Reports, Journal Year: 2024, Volume and Issue: 44(2), P. 321 - 332

Published: April 14, 2024

Abstract Aims To determine the prevalence and impact of emotional blunting (EB) in patients with major depressive disorder (MDD) Japan, identify treatment needs for EB using patients' perceptions attitudes. Methods Eligible Japan (aged 18–59 years) who reported a diagnosis MDD antidepressant medication use >3 months were eligible to complete an online survey. The primary outcome was EB, self‐reported validated screening question. Secondary outcomes included correlation between symptoms (measured by Oxford Depression Questionnaire [ODQ]) scores on Patient Health 9‐item (PHQ‐9), Generalized Anxiety Disorder 7‐item (GAD‐7), Work Social Adjustment Scale (WSAS), EuroQol 5‐Dimension 5‐Levels questionnaire (EQ‐5D‐5L). Descriptive questions used explore attitudes toward EB. Results In total, 3376 analysis (56% male; 48% aged 50–59 years). Overall, 67.1% 10% rating these as severe. mean (SD) ODQ total score 78.2 (21.5), which increased worsening symptoms. There correlations PHQ‐9, GAD‐7, WSAS, EQ‐5D‐5L (correlation coefficients: 0.67, 0.55, 0.56, −0.51, respectively; all p < 0.0001). analyses showed that one‐third reporting did not tell their physician, two‐thirds finding distressing likely affect recovery. Conclusion is important clinical issue be considered alongside functional recovery when managing MDD.

Language: Английский

Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder DOI Creative Commons
Marcin Siwek, Adrian Andrzej Chrobak, Anna Julia Krupa

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 23, 2025

Introduction Early research on the pharmacotherapy for major depressive disorder (MDD) has largely focused symptomatic improvements, whereas this focus shifted to functioning and quality of life in recent years. Studies have confirmed that antidepressants generally improve functional outcomes MDD, but very few works compared efficacies specific drugs. The present work aims compare impacts trazodone once-a-day extended-release (XR) vs selective serotonin reuptake inhibitors (SSRIs) health status MDD. Methods Data were gathered from 180 subjects through a naturalistic observation study effectiveness depression (TED) analyzed. TED participants received XR SSRIs flexible doses 12 weeks. health-related (HRQoL) evaluated using EQ-5D-5L tool at baseline as well 2, 4, 8, Results At baseline, treated with presented similar profiles HRQoL values respect mobility, self-care, anxiety/depression dimensions along lower scores usual activities, pain/discomfort, overall HRQoL, status. Both improved MDD patients all subsequent timepoints. Compared SSRIs, provided greater improvements terms measures more often participant HRQoL. More reported mixed changes their SSRI group than group. Discussion Health both treatment arms, preferable vs.

Language: Английский

Citations

0
A web‐based survey on the occurrence of emotional blunting in patients with major depressive disorder in Japan: Patient perceptions and attitudes DOI Creative Commons
Toshiaki Kikuchi, Jun‐ichi Iga, Masato Oosawa

et al.

Neuropsychopharmacology Reports, Journal Year: 2024, Volume and Issue: 44(2), P. 321 - 332

Published: April 14, 2024

Abstract Aims To determine the prevalence and impact of emotional blunting (EB) in patients with major depressive disorder (MDD) Japan, identify treatment needs for EB using patients' perceptions attitudes. Methods Eligible Japan (aged 18–59 years) who reported a diagnosis MDD antidepressant medication use >3 months were eligible to complete an online survey. The primary outcome was EB, self‐reported validated screening question. Secondary outcomes included correlation between symptoms (measured by Oxford Depression Questionnaire [ODQ]) scores on Patient Health 9‐item (PHQ‐9), Generalized Anxiety Disorder 7‐item (GAD‐7), Work Social Adjustment Scale (WSAS), EuroQol 5‐Dimension 5‐Levels questionnaire (EQ‐5D‐5L). Descriptive questions used explore attitudes toward EB. Results In total, 3376 analysis (56% male; 48% aged 50–59 years). Overall, 67.1% 10% rating these as severe. mean (SD) ODQ total score 78.2 (21.5), which increased worsening symptoms. There correlations PHQ‐9, GAD‐7, WSAS, EQ‐5D‐5L (correlation coefficients: 0.67, 0.55, 0.56, −0.51, respectively; all p < 0.0001). analyses showed that one‐third reporting did not tell their physician, two‐thirds finding distressing likely affect recovery. Conclusion is important clinical issue be considered alongside functional recovery when managing MDD.

Language: Английский

Citations

2